Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDuke University
About this trial
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Eligibility criteria
Qualifiers
Adults with type 2 diabetes (T2D)
Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR
Disqualifiers
None
Trial design
Treatments tested in this trial
- (IRIS-CKD Screening Program): Home Kit
- (IRIS-CKD Screening Program): Standard Lab Order
Treatment groups
750 Participants
are divided into 2 treatment groupsLocations
7Alabama
University of Alabama35233, Birmingham United States
Florida
Orlando Health33701, St. Petersburg United States
Michigan
University of Michigan48109, Ann Arbor United States
Minnesota
Essentia Health55805, Duluth United States
Sponsors and collaborators
Duke University
Lead sponsor
Bayer
Collaborator
Boehringer Ingelheim
Collaborator
Eli Lilly and Company
Collaborator
Source ClinicalTrials.gov